PL1984503T5 - Zmodyfikowany czynnik krzepnięcia viia o wydłużonym okresie półtrwania - Google Patents

Zmodyfikowany czynnik krzepnięcia viia o wydłużonym okresie półtrwania

Info

Publication number
PL1984503T5
PL1984503T5 PL07703248T PL07703248T PL1984503T5 PL 1984503 T5 PL1984503 T5 PL 1984503T5 PL 07703248 T PL07703248 T PL 07703248T PL 07703248 T PL07703248 T PL 07703248T PL 1984503 T5 PL1984503 T5 PL 1984503T5
Authority
PL
Poland
Prior art keywords
life
coagulation factor
factor viia
extended half
modified coagulation
Prior art date
Application number
PL07703248T
Other languages
English (en)
Other versions
PL1984503T3 (pl
Inventor
Thomas Weimer
Stefan Schulte
Ulrich Kronthaler
Wiegand Lang
Uwe Liebing
Wilfried Wormsbächer
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36762937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1984503(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL1984503T3 publication Critical patent/PL1984503T3/pl
Publication of PL1984503T5 publication Critical patent/PL1984503T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL07703248T 2006-02-06 2007-02-03 Zmodyfikowany czynnik krzepnięcia viia o wydłużonym okresie półtrwania PL1984503T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06002359A EP1816201A1 (en) 2006-02-06 2006-02-06 Modified coagulation factor VIIa with extended half-life
EP07703248.0A EP1984503B2 (en) 2006-02-06 2007-02-03 Modified coagulation factor viia with extended half-life
PCT/EP2007/000937 WO2007090584A1 (en) 2006-02-06 2007-02-03 Modified coagulation factor vila with extended half-life

Publications (2)

Publication Number Publication Date
PL1984503T3 PL1984503T3 (pl) 2014-12-31
PL1984503T5 true PL1984503T5 (pl) 2019-02-28

Family

ID=36762937

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07703248T PL1984503T5 (pl) 2006-02-06 2007-02-03 Zmodyfikowany czynnik krzepnięcia viia o wydłużonym okresie półtrwania

Country Status (15)

Country Link
US (3) US8765915B2 (pl)
EP (3) EP1816201A1 (pl)
JP (2) JP5726404B2 (pl)
KR (2) KR101439817B1 (pl)
CN (1) CN101379189B (pl)
AU (1) AU2007214011B9 (pl)
BR (1) BRPI0707513A2 (pl)
CA (1) CA2636671C (pl)
DK (1) DK1984503T4 (pl)
ES (2) ES2793325T3 (pl)
HK (1) HK1129421A1 (pl)
MX (1) MX2008009893A (pl)
PL (1) PL1984503T5 (pl)
RU (1) RU2466141C2 (pl)
WO (1) WO2007090584A1 (pl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009533364A (ja) * 2006-04-11 2009-09-17 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 治療用ポリペプチドのインビボでの回収を増大させる方法
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
WO2007144173A1 (en) * 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US20110154516A1 (en) * 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
KR101507718B1 (ko) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
AU2010258898B8 (en) 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
AU2010284977A1 (en) 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
EP2470559B1 (en) * 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011028344A2 (en) * 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
EP2499165B1 (en) 2009-11-13 2016-09-14 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2011092242A1 (en) * 2010-01-28 2011-08-04 Novo Nordisk Health Care Ag Factor vii fusion polypeptides
KR101331101B1 (ko) 2010-06-04 2013-11-19 에스케이케미칼주식회사 인자 ｖｉｉ 활성을 갖는 융합 단백질
WO2012006635A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Processable single chain molecules and polypeptides made using same
EA037095B1 (ru) 2010-07-09 2021-02-05 Биовератив Терапьютикс Инк. Способ лечения гемофилии в и эпизодов кровотечения
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP2012125190A (ja) * 2010-12-15 2012-07-05 Kakei Gakuen 会合ユニット作製用リンカーペプチド
ES2675353T3 (es) 2011-02-04 2018-07-10 Octapharma Ag Procedimiento para inactivación/eliminación de factores de coagulación por precipitación
JP6108630B2 (ja) * 2011-10-06 2017-04-05 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅ Ｃｏ．，Ｌｔｄ． 血液凝固因子ＶＩＩ及びＶＩＩａ誘導体、それらを含む結合体及び複合体、並びにそれらの使用
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
US10202595B2 (en) * 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US9175279B1 (en) 2013-03-15 2015-11-03 Csl Limited Method of purifying factor VII and/or factor VIIa
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
RU2016144159A (ru) * 2014-04-11 2018-05-11 СиЭсЭл ЛИМИТЕД Белок-фактор fviia с увеличенным периодом полужизни для профилактики и лечения кровотечения, и его режимы дозирования
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
CN106397571A (zh) * 2015-07-31 2017-02-15 李金松 一种新型羧基末端肽及长效白介素7
CN106397570B (zh) * 2015-07-31 2019-11-15 袁武梅 一种羧基末端肽及长效干扰素
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
GB201520021D0 (en) 2015-11-13 2015-12-30 Asterion Ltd Fusion polypeptide
AU2016363789B2 (en) * 2015-12-02 2022-06-02 CSL Behring Lengnau AG Improved media for the expression of recombinant vitamin K-dependent proteins
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
CN108779165B (zh) 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
CN106279436B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 活化的人凝血因子vii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
JP2019530672A (ja) * 2016-09-13 2019-10-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 第ｖｉｉａ因子グリコフォーム
PE20191319A1 (es) * 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
EP3538134B1 (en) 2016-11-11 2021-12-29 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
CN108727486A (zh) * 2017-04-24 2018-11-02 舒泰神（北京）生物制药股份有限公司 长效神经生长因子、制备方法及其组合物
CA3068098A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
KR102134571B1 (ko) * 2018-06-15 2020-07-16 주식회사 알테오젠 혈액응고인자 VII/VIIa 융합단백질의 제조 방법
JP2022520886A (ja) * 2019-03-27 2022-04-01 シギロン セラピューティクス， インコーポレイテッド 第ｖｉｉ因子療法のための組成物、デバイス及び方法
EP3968988A1 (en) 2019-05-17 2022-03-23 Universität Zürich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses
CN117136068A (zh) 2021-02-01 2023-11-28 瑞士杰特贝林生物制品有限公司 治疗或预防出血性中风后不良继发性神经学后果的方法
CA3217518A1 (en) 2021-05-07 2022-11-10 Rebecca Butcher Expression system for producing a recombinant haptoglobin (hp) beta chain
TW202423475A (zh) 2022-09-02 2024-06-16 瑞士商Ｃｓｌ貝林股份有限公司 用於治療或預防過度勃起反應或勃起功能障礙之血紅素結合蛋白

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019A (en) * 1847-03-13 Shirt-bosom
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CN1026994C (zh) 1987-07-28 1994-12-14 吉斯特布罗卡德斯股份有限公司 在克鲁维酵母宿主生产所需肽的方法
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
WO1990001063A1 (en) * 1988-07-23 1990-02-08 Delta Biotechnology Limited New secretory leader sequences
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5667986A (en) * 1989-10-18 1997-09-16 Delta Biotechnology Limited Yeast promoter for expressing heterologous polypeptides
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
FR2676070B1 (fr) 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
US5646012A (en) * 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
FR2694294B1 (fr) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisateur.
DE4226971C2 (de) * 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
CA2162726A1 (en) 1993-05-21 1994-12-08 Kathleen L. Berkner Modified factor vii
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DK144093D0 (pl) 1993-12-23 1993-12-23 Novo Nordisk As
FR2719593B1 (fr) 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
EP0793504B1 (en) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
CA2246431A1 (en) 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
AU3972797A (en) * 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
EP1042342A4 (en) 1997-10-09 2003-04-09 Human Genome Sciences Inc 53 PROTEINS OF HUMAN ORIGIN
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
WO1999059622A1 (en) 1998-05-20 1999-11-25 Genentech, Inc. Treatment for hemophilia
WO1999066054A2 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Erythropoietin analog-human serum albumin fusion protein
DE69942207D1 (de) 1998-08-25 2010-05-12 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
IL147269A0 (en) 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
EP1224309A2 (en) 1999-10-21 2002-07-24 Monsanto Company Post-translational modification of recombinant proteins produced in plants
AU783512B2 (en) 2000-02-11 2005-11-03 Bayer Healthcare Llc Factor VII or VIIa-like molecules
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6946134B1 (en) * 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002004598A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Improvement of cell culture performance by inhibitors of pyruvate dehydrogenase kinase
KR100880624B1 (ko) 2000-10-02 2009-01-30 노보 노르디스크 헬스 케어 악티엔게젤샤프트 비타민 ｋ-의존 단백질의 생산 방법
KR20030060915A (ko) 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
KR20080085082A (ko) * 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1402049A4 (en) 2001-03-12 2004-09-01 Progenetics Llc PRODUCTION OF HIGH LEVELS OF TRANSGENIC FACTOR VIII WITH STUDY STUDY, AND ITS THERAPEUTIC APPLICATIONS
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
CA2446739A1 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
AU2002310438B2 (en) 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
CN102180944A (zh) * 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
ES2500918T3 (es) * 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
EP1463942B2 (en) 2001-12-21 2012-06-20 Immunex Corporation Methods for purifying protein
JP2005516607A (ja) * 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
CN101044154A (zh) 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
ES2343681T3 (es) 2002-04-29 2010-08-06 Stichting Sanquin Bloedvoorziening Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad.
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1444986A1 (en) 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20070041987A1 (en) 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
ES2333598T5 (es) * 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
CN1871252A (zh) 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
WO2005111225A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
EP1598367A1 (en) 2004-05-18 2005-11-23 ZLB Behring GmbH Modified coagulation factors with enhanced stability and their derivatives
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
DE602005021509D1 (de) 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
EP1874815A1 (en) 2005-04-14 2008-01-09 CSL Behring GmbH Modified coagulation factor viii with enhanced stability and its derivates
JP2009504157A (ja) 2005-08-12 2009-02-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009533364A (ja) 2006-04-11 2009-09-17 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 治療用ポリペプチドのインビボでの回収を増大させる方法
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
ES2566385T3 (es) 2007-02-12 2016-04-12 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal

Also Published As

Publication number Publication date
JP5726404B2 (ja) 2015-06-03
ES2504517T5 (es) 2019-01-24
RU2466141C2 (ru) 2012-11-10
EP1984503B2 (en) 2018-08-15
WO2007090584A1 (en) 2007-08-16
ES2504517T3 (es) 2014-10-08
PL1984503T3 (pl) 2014-12-31
EP2233576B1 (en) 2020-04-08
EP1816201A1 (en) 2007-08-08
CN101379189B (zh) 2014-09-03
US20140356346A1 (en) 2014-12-04
CN101379189A (zh) 2009-03-04
DK1984503T4 (en) 2018-12-03
DK1984503T3 (da) 2014-09-15
EP1984503A1 (en) 2008-10-29
EP2233576A1 (en) 2010-09-29
KR20140066793A (ko) 2014-06-02
US20090298760A1 (en) 2009-12-03
RU2008132760A (ru) 2010-02-20
CA2636671A1 (en) 2007-08-16
EP1984503B1 (en) 2014-07-09
AU2007214011B2 (en) 2013-01-17
JP2009525724A (ja) 2009-07-16
KR101579083B1 (ko) 2015-12-21
US8765915B2 (en) 2014-07-01
CA2636671C (en) 2016-08-30
US20170080061A1 (en) 2017-03-23
HK1129421A1 (en) 2009-11-27
ES2793325T3 (es) 2020-11-13
AU2007214011B9 (en) 2013-05-30
KR101439817B1 (ko) 2014-10-02
MX2008009893A (es) 2008-11-06
BRPI0707513A2 (pt) 2011-05-10
KR20080109750A (ko) 2008-12-17
JP2013188230A (ja) 2013-09-26
AU2007214011A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
PL1984503T5 (pl) Zmodyfikowany czynnik krzepnięcia viia o wydłużonym okresie półtrwania
EP1956989A4 (en) REVERSE ANGLE THREAD WITH ANTI-ESCAPE FREE SPACE
EP2209394A4 (en) Armtasche
EP2093337A4 (en) MULTIPURPOSE PIECE
DE102006010651A8 (de) Kombinationswerkzeug mit Stirnaussparung
GB0714901D0 (en) Saw
IL182704A0 (en) Klipped kippahs: the kippahs with built-in clips
PL2099584T3 (pl) Łączący zespół
PL1927646T3 (pl) Środek nawaniający o polepszonej trwałości
GB0601471D0 (en) The cardioprotector
HK1132994A1 (en) Mtki quinazoline derivatives mtki
GB2442925B (en) Keyboard with extended connection
GB0813307D0 (en) Retro-reflector
IL206095A0 (en) Chemically modified factor ix
EP2028971A4 (en) WORK AREA
HK1126956A1 (en) Compositions with enhanced elasticizing activity
GB2444938B (en) Impeller Arrangement
FR2895998B1 (fr) Piece composite armee
EP2080759A4 (en) INDUCER OF -GLOBINE GAMA
GB0610498D0 (en) Modified molecule
GB0602141D0 (en) The turboramjet
HU0600878D0 (en) Sausage-meat with swine-bread
FIU20060435U0 (fi) Kiinnityskappale
FIU20060314U0 (fi) Kiinnityslevy
GB0613444D0 (en) Corky:the leader